MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023011225

Медицинская библиотека · Blood advances · 2024

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.

Firestone Ross S, McAvoy Devin, Shekarkhand Tala, Serrano Edith, Hamadeh Issam, Wang Alice, Zhu Menglei, Qin Wei Ge, Patel Dhwani, Tan Carlyn R, Hultcrantz Malin, Mailankody Sham, Hassoun Hani, Shah Urvi S, Korde Neha, Maclachlan Kylee H, Landau Heather J, Scordo Michael, Shah Gunjan L, Lahoud Oscar B, Giralt Sergio, Murata Kazunori, Hosszu Kinga K, Chung David J, Lesokhin Alexander M, Usmani Saad Z

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.

Для цитирования: Firestone Ross S, McAvoy Devin, Shekarkhand Tala, Serrano Edith, Hamadeh Issam, Wang Alice, Zhu Menglei, Qin Wei Ge, Patel Dhwani, Tan Carlyn R, Hultcrantz Malin, Mailankody Sham, Hassoun Hani, Shah Urvi S, Korde Neha, Maclachlan Kylee H, Landau Heather J, Scordo Michael, Shah Gunjan L, Lahoud Oscar B, Giralt Sergio, Murata Kazunori, Hosszu Kinga K, Chung David J, Lesokhin Alexander M, Usmani Saad Z. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.. Blood advances. 2024. DOI: 10.1182/bloodadvances.2023011225.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.